This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Laekna Therapeutics Shanghai Co. Ltd. (developing both small-molecule and antibody-targeted drugs for cancer and liver diseases) raised $18.5mm through a Series A round led by OrbiMed Asia, with AnlongMed also participating. The 2016 start-up plans to use the funding to progress its pipeline. Laekna currently has three oncology candidates, including Phase II LAE001 (CFG920), an oral CYP17 inhibitor for prostate cancer, in-licensed from Novartis last year. It is also developing compounds for liver diseases, including NASH and hepatic cirrhosis.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?